Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy

Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy

Activating mutations in FLT3 confer poor prognosis for individuals with acute myeloid leukemia (AML). Clinically active investigational FLT3 inhibitors can achieve complete remissions but their utility has been hampered by acquired resistance and myelosuppression attributed to a ‘synthetic lethal to...

Full description

Bibliographic Details
Main Authors: Alexander A Warkentin, Michael S Lopez, Elisabeth A Lasater, Kimberly Lin, Bai-Liang He, Anskar YH Leung, Catherine C Smith, Neil P Shah, Kevan M Shokat
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2014-12-01
Series:eLife
Subjects:
staurosporine
protein kinase
leukemia
FLT3
KIT
chemical synthesis
Online Access:https://elifesciences.org/articles/03445

Internet

https://elifesciences.org/articles/03445

Similar Items